Cargando…

Alteration in the Cerebrospinal Fluid Lipidome in Parkinson’s Disease: A Post-Mortem Pilot Study

Lipid metabolism is clearly associated to Parkinson’s disease (PD). Although lipid homeostasis has been widely studied in multiple animal and cellular models, as well as in blood derived from PD individuals, the cerebrospinal fluid (CSF) lipidomic profile in PD remains largely unexplored. In this st...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernández-Irigoyen, Joaquín, Cartas-Cejudo, Paz, Iruarrizaga-Lejarreta, Marta, Santamaría, Enrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146703/
https://www.ncbi.nlm.nih.gov/pubmed/33946950
http://dx.doi.org/10.3390/biomedicines9050491
_version_ 1783697457577721856
author Fernández-Irigoyen, Joaquín
Cartas-Cejudo, Paz
Iruarrizaga-Lejarreta, Marta
Santamaría, Enrique
author_facet Fernández-Irigoyen, Joaquín
Cartas-Cejudo, Paz
Iruarrizaga-Lejarreta, Marta
Santamaría, Enrique
author_sort Fernández-Irigoyen, Joaquín
collection PubMed
description Lipid metabolism is clearly associated to Parkinson’s disease (PD). Although lipid homeostasis has been widely studied in multiple animal and cellular models, as well as in blood derived from PD individuals, the cerebrospinal fluid (CSF) lipidomic profile in PD remains largely unexplored. In this study, we characterized the post-mortem CSF lipidomic imbalance between neurologically intact controls (n = 10) and PD subjects (n = 20). The combination of dual extraction with ultra-performance liquid chromatography-electrospray ionization quadrupole-time-of-flight mass spectrometry (UPLC-ESI-qToF-MS/MS) allowed for the monitoring of 257 lipid species across all samples. Complementary multivariate and univariate data analysis identified that glycerolipids (mono-, di-, and triacylglycerides), saturated and mono/polyunsaturated fatty acids, primary fatty amides, glycerophospholipids (phosphatidylcholines, phosphatidylethanolamines), sphingolipids (ceramides, sphingomyelins), N-acylethanolamines and sterol lipids (cholesteryl esters, steroids) were significantly increased in the CSF of PD compared to the control group. Interestingly, CSF lipid dyshomeostasis differed depending on neuropathological staging and disease duration. These results, despite the limitation of being obtained in a small population, suggest extensive CSF lipid remodeling in PD, shedding new light on the deployment of CSF lipidomics as a promising tool to identify potential lipid markers as well as discriminatory lipid species between PD and other atypical parkinsonisms.
format Online
Article
Text
id pubmed-8146703
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81467032021-05-26 Alteration in the Cerebrospinal Fluid Lipidome in Parkinson’s Disease: A Post-Mortem Pilot Study Fernández-Irigoyen, Joaquín Cartas-Cejudo, Paz Iruarrizaga-Lejarreta, Marta Santamaría, Enrique Biomedicines Article Lipid metabolism is clearly associated to Parkinson’s disease (PD). Although lipid homeostasis has been widely studied in multiple animal and cellular models, as well as in blood derived from PD individuals, the cerebrospinal fluid (CSF) lipidomic profile in PD remains largely unexplored. In this study, we characterized the post-mortem CSF lipidomic imbalance between neurologically intact controls (n = 10) and PD subjects (n = 20). The combination of dual extraction with ultra-performance liquid chromatography-electrospray ionization quadrupole-time-of-flight mass spectrometry (UPLC-ESI-qToF-MS/MS) allowed for the monitoring of 257 lipid species across all samples. Complementary multivariate and univariate data analysis identified that glycerolipids (mono-, di-, and triacylglycerides), saturated and mono/polyunsaturated fatty acids, primary fatty amides, glycerophospholipids (phosphatidylcholines, phosphatidylethanolamines), sphingolipids (ceramides, sphingomyelins), N-acylethanolamines and sterol lipids (cholesteryl esters, steroids) were significantly increased in the CSF of PD compared to the control group. Interestingly, CSF lipid dyshomeostasis differed depending on neuropathological staging and disease duration. These results, despite the limitation of being obtained in a small population, suggest extensive CSF lipid remodeling in PD, shedding new light on the deployment of CSF lipidomics as a promising tool to identify potential lipid markers as well as discriminatory lipid species between PD and other atypical parkinsonisms. MDPI 2021-04-29 /pmc/articles/PMC8146703/ /pubmed/33946950 http://dx.doi.org/10.3390/biomedicines9050491 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Fernández-Irigoyen, Joaquín
Cartas-Cejudo, Paz
Iruarrizaga-Lejarreta, Marta
Santamaría, Enrique
Alteration in the Cerebrospinal Fluid Lipidome in Parkinson’s Disease: A Post-Mortem Pilot Study
title Alteration in the Cerebrospinal Fluid Lipidome in Parkinson’s Disease: A Post-Mortem Pilot Study
title_full Alteration in the Cerebrospinal Fluid Lipidome in Parkinson’s Disease: A Post-Mortem Pilot Study
title_fullStr Alteration in the Cerebrospinal Fluid Lipidome in Parkinson’s Disease: A Post-Mortem Pilot Study
title_full_unstemmed Alteration in the Cerebrospinal Fluid Lipidome in Parkinson’s Disease: A Post-Mortem Pilot Study
title_short Alteration in the Cerebrospinal Fluid Lipidome in Parkinson’s Disease: A Post-Mortem Pilot Study
title_sort alteration in the cerebrospinal fluid lipidome in parkinson’s disease: a post-mortem pilot study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8146703/
https://www.ncbi.nlm.nih.gov/pubmed/33946950
http://dx.doi.org/10.3390/biomedicines9050491
work_keys_str_mv AT fernandezirigoyenjoaquin alterationinthecerebrospinalfluidlipidomeinparkinsonsdiseaseapostmortempilotstudy
AT cartascejudopaz alterationinthecerebrospinalfluidlipidomeinparkinsonsdiseaseapostmortempilotstudy
AT iruarrizagalejarretamarta alterationinthecerebrospinalfluidlipidomeinparkinsonsdiseaseapostmortempilotstudy
AT santamariaenrique alterationinthecerebrospinalfluidlipidomeinparkinsonsdiseaseapostmortempilotstudy